Interfaculty Institute of Microbiology and Infection Medicine

New Transregional Collaborative Research Center granted to Tübingen and Bonn under leadership of the IMIT

Antibiotics – more than other therapeutic agents – have increased human life expectancy. New antibiotic classes are urgently needed but their discovery and development are challenging. There are still vast gaps in knowledge, both regarding the modes of action of antibiotics as well as the biology of bacterial cells exposed to these agents. Within the new TRR 261, an interdisciplinary team of scientists from the Universities of Tübingen and Bonn will work towards an improved understanding of antibiotic effects on pathogenic “target cells” and antibiotic biosynthesis in “producer cells”. Increased fundamental knowledge will help to better produce, optimise and develop novel antibiotics in the future.


Prof. Dr. Heike Brötz-Oesterhelt
Microbial Bioactive Compounds
Auf der Morgenstelle 28
72076 Tübingen
Fon: +49 7071 29 74706
Fax: +49 7071 29 5094
E-Mail: heike.broetz-oesterheltspam

Further information here

New Cluster of Excellence for Tübingen with significant contribution of the IMIT

The goal is to find new, targeted agents which will have a positive effect on the microbiome. We know that useful bacteria help to keep down the harmful ones. In order to understand and exploit the underlying mechanisms, the Cluster of Excellence will bring together researchers from the fields of molecular, bioinformatics and clinical disciplines. The Cluster speakers are Professor Andreas Peschel and Professor Heike Brötz-Oesterhelt of the Interfaculty Institute of Microbiology and Infection Medicine at the University, along with Professor Ruth Ley, Director of the Max Planck Institute for Developmental Biology. The University Hospitals and the German Center for Infection Research (DZIF) are also partners in the Cluster.

Press release